$14.00
▼ -0.6% Today
as of Sep 4, 16:49 ET
Last 30 days
Recent Press Releases & News
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
Hutchmed Signs Cancer Treatment Licensing Agreement With GSK; Shares Rise Pre-Bell
Overview
52-week range
$9.77
$18
50% of range
Avg surprise (last 0)
—
Avg reaction (last 0)
—
Latest IV / EM
227%
EM ±35.5% · $15 · Sep 18